New Data Highlights Long Term Tolerability And Sustained Benefits Of The Exelon Patch In The Treatment Of Alzheimer’s Disease

Exelon (rivastigmine transdermal patch), which delivers rivastigmine to patients through the skin into the bloodstream, has been shown to be well tolerated by Alzheimer’s disease (AD) patients for up to one year of treatment with sustained benefits. The findings come from the 28-week, open-label extension phase of the IDEAL ( I nvestigation of trans D ermal E xelon in Alz heimer’s disease) trial. [click link for full article]

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on August 29th, 2007